{
  "_metadata": {
    "version": "2.2",
    "ticker": "KYMR",
    "asset_name": "KT-485",
    "last_updated": "2026-02-06",
    "sources": [
      {
        "id": "kymr_corporate_2026",
        "type": "corporate_presentation",
        "title": "Kymera Therapeutics Corporate Presentation January 2026",
        "date": "2026-01",
        "slides": 67,
        "url": null
      }
    ]
  },
  "asset": {
    "name": "KT-485",
    "alternative_names": [
      "SAR447971"
    ],
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "stage": "IND-enabling complete; Phase 1 expected 2026",
    "modality": "Heterobifunctional degrader",
    "ownership": "Partnered with Sanofi",
    "one_liner": "Second-generation oral IRAK4 degrader - combined activity of upstream biologics (anti-IL-1/18/33/36) in a pill"
  },
  "target": {
    "name": "IRAK4",
    "full_name": "Interleukin 1 Receptor Associated Kinase 4",
    "class": "Scaffolding Kinase",
    "pathway": "IL-1R/TLR signaling → Th1/Th2/Th17 inflammation",
    "biology": {
      "simple_explanation": "IRAK4 is a master regulator of innate immunity that sits at the crossroads of multiple inflammatory pathways. When cytokines like IL-1, IL-18, IL-33, or IL-36 bind their receptors, or when TLRs detect danger signals, IRAK4 is the critical node that transmits the signal to cause inflammation.",
      "dual_function": {
        "kinase_activity": "Phosphorylates downstream targets",
        "scaffolding_function": "Physically brings together signaling components (MyD88, IRAK1/2) in the 'Myddosome' complex",
        "key_insight": "Traditional kinase inhibitors can only block ~50% of IRAK4 function. DEGRADATION eliminates BOTH kinase AND scaffolding functions - the only way to fully block the pathway"
      },
      "pathway_detail": {
        "upstream_signals": [
          {
            "cytokine": "IL-1α/IL-1β",
            "receptor": "IL-1R"
          },
          {
            "cytokine": "IL-18",
            "receptor": "IL-18R"
          },
          {
            "cytokine": "IL-33",
            "receptor": "ST2"
          },
          {
            "cytokine": "IL-36",
            "receptor": "IL-36R"
          },
          {
            "ligands": "TLR agonists (PAMPs/DAMPs)",
            "receptors": "TLR2, TLR4, TLR5, TLR7, TLR8, TLR9"
          }
        ],
        "signaling_cascade": "Receptor activation → MyD88 recruitment → IRAK4 → IRAK1/2 → TRAF6 → NF-κB → Inflammatory gene transcription",
        "outputs": "Th1, Th2, and Th17 inflammatory cytokines"
      },
      "why_obligate_node": "IRAK4 is required for ALL MyD88-dependent signaling. Without functional IRAK4, the entire IL-1R/TLR pathway is blocked."
    },
    "why_good_target": {
      "genetic_validation": {
        "finding": "Adult humans with IRAK4 null mutations are HEALTHY",
        "implication": "Natural experiment proving complete IRAK4 elimination is safe",
        "caveat": "IRAK4-null children have increased susceptibility to pyogenic bacterial infections, but this resolves with age",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 64,
          "verified": false
        }
      },
      "clinical_pathway_validation": {
        "description": "Multiple drugs validate the pathways upstream and downstream of IRAK4",
        "validated_pathways": [
          {
            "cytokine": "IL-1α/IL-1β",
            "drugs": "Anakinra, Canakinumab, Rilonacept",
            "indications": "RA, CAPS, HS, AD, Recurrent Pericarditis, Gout"
          },
          {
            "cytokine": "IL-18",
            "drugs": "In development",
            "indications": "AD, Macrophage Activation Syndrome"
          },
          {
            "cytokine": "IL-36",
            "drugs": "Spesolimab (anti-IL-36R)",
            "indications": "Generalized Pustular Psoriasis (GPP)"
          },
          {
            "cytokine": "IL-33",
            "drugs": "Itepekimab, Astegolimab",
            "indications": "Asthma, COPD"
          },
          {
            "pathway": "IRAK4 kinase",
            "drugs": "IRAK4 kinase inhibitors (Phase 1/2)",
            "indications": "RA"
          }
        ],
        "key_insight": "IRAK4 degradation could achieve the COMBINED activity of anti-IL-1 + anti-IL-18 + anti-IL-33 + anti-IL-36 biologics in one oral pill"
      }
    },
    "why_degrader_not_inhibitor": {
      "inhibitor_limitation": "IRAK4 has essential SCAFFOLDING function that kinase inhibitors cannot block",
      "published_evidence": "Clinical IRAK4 kinase inhibitors have shown limited efficacy, likely because scaffolding function remains",
      "degrader_advantage": "Complete protein elimination blocks both kinase AND scaffolding - full pathway shutdown"
    }
  },
  "mechanism": {
    "type": "Heterobifunctional degrader (PROTAC)",
    "e3_ligase": "Not specified",
    "how_it_works": "KT-485 binds IRAK4 and recruits an E3 ligase to ubiquitinate and degrade the entire IRAK4 protein, eliminating both kinase and scaffolding functions"
  },
  "regulatory": null,
  "partnership": {
    "partner": "Sanofi",
    "deal_date": "Prior to January 2026",
    "upfront_payment": "$150M (received for KT-474 deal)",
    "total_milestones": "Up to $2B",
    "milestone_breakdown": null,
    "royalty_rates": "Tiered double-digit",
    "opt_in_rights": null,
    "territory": null,
    "who_controls_development": "Sanofi (development lead); Kymera provides discovery and research support",
    "strategic_value": [
      "Validates IRAK4 degradation approach",
      "Sanofi has deep I&I expertise and commercial infrastructure",
      "Non-dilutive funding",
      "Milestone/royalty economics preserved"
    ],
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 51,
      "verified": false
    }
  },
  "indications": {
    "lead": {
      "name": "Hidradenitis Suppurativa (HS)",
      "patient_population": "Part of >140M across all indications",
      "rationale": "IL-1 pathway validated; high unmet need; no oral options"
    },
    "expansion": [
      {
        "name": "Atopic Dermatitis (AD)",
        "rationale": "IL-18, IL-33 validated"
      },
      {
        "name": "Asthma",
        "rationale": "IL-33 validated"
      },
      {
        "name": "COPD",
        "rationale": "IL-33 validated"
      },
      {
        "name": "Rheumatoid Arthritis (RA)",
        "rationale": "IL-1 validated; IRAK4i in trials"
      },
      {
        "name": "SLE",
        "rationale": "TLR pathway"
      },
      {
        "name": "UC/CD (IBD)",
        "rationale": "IL-1/TLR pathway"
      }
    ],
    "total_addressable_patients": ">140M",
    "current_penetration": "3% on advanced systemic therapies",
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 51,
      "verified": false
    }
  },
  "market_opportunity": {
    "total_addressable_market": ">$55B combined",
    "current_penetration": "3% on advanced therapy",
    "unique_value_proposition": "Combined activity of multiple upstream biologics in one oral drug",
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 51,
      "verified": false
    }
  },
  "pharmacology": null,
  "kt485_vs_kt474": {
    "description": "KT-485 is the second-generation IRAK4 degrader that improves on KT-474",
    "comparison": {
      "kt474_issues": [
        "QTc prolongation signal observed",
        "Development discontinued in favor of KT-485"
      ],
      "kt485_improvements": [
        "No QTc signal",
        "Increased selectivity",
        "Increased potency",
        "Prioritized by Sanofi for clinical development"
      ]
    },
    "analyst_note": "The QTc issue with KT-474 was a setback, but KT-485 addresses this. Sanofi's decision to advance KT-485 validates that the improvement is meaningful.",
    "source": {
      "id": "kymr_corporate_2026",
      "slide": 51,
      "verified": false
    }
  },
  "clinical_data": {
    "status": "No human data for KT-485 yet",
    "kt474_learnings": "Learnings from KT-474 clinical studies will be applied to accelerate KT-485 development",
    "ind_enabling": "Complete for KT-485"
  },
  "upcoming_trials": {
    "phase1": {
      "description": "Phase 1 clinical trial",
      "timing": "Expected to initiate in 2026",
      "sponsor": "Sanofi (leading development)",
      "kymera_role": "Learnings and support from KT-474 program",
      "source": {
        "id": "kymr_corporate_2026",
        "slide": 51,
        "verified": false
      }
    }
  },
  "biomarkers": null,
  "differentiation_claims": {
    "claims": [
      {
        "claim": "Degrader blocks both kinase AND scaffolding function vs kinase inhibitors blocking only kinase",
        "comparator": "IRAK4 kinase inhibitors (Pfizer, others)",
        "evidence_level": "mechanistic_rationale",
        "supporting_data": "IRAK4 has essential scaffolding function in Myddosome assembly; kinase inhibitors leave scaffolding intact, blocking only ~50% of function",
        "caveat": null,
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 51,
          "verified": false
        }
      },
      {
        "claim": "Oral once-daily dosing vs injectable biologics",
        "comparator": "Anti-IL-1 biologics (Anakinra, Canakinumab), Anti-IL-36R (Spesolimab)",
        "evidence_level": "head_to_head",
        "supporting_data": "KT-485 is oral; Anakinra/Canakinumab/Spesolimab are injectable",
        "caveat": null,
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 51,
          "verified": false
        }
      },
      {
        "claim": "Combined activity of anti-IL-1 + anti-IL-18 + anti-IL-33 + anti-IL-36 in one molecule",
        "comparator": "Spesolimab (anti-IL-36R only), Anakinra (anti-IL-1 only)",
        "evidence_level": "mechanistic_rationale",
        "supporting_data": "IRAK4 sits at convergence of IL-1R, IL-18R, ST2, IL-36R signaling; degradation blocks all simultaneously",
        "caveat": null,
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 51,
          "verified": false
        }
      },
      {
        "claim": "No QTc signal vs first-generation KT-474",
        "comparator": "KT-474 (first-generation IRAK4 degrader)",
        "evidence_level": "preclinical_only",
        "supporting_data": "KT-474 had QTc prolongation signal; KT-485 designed to eliminate this; Sanofi prioritized KT-485",
        "caveat": "Based on preclinical data only, not confirmed in humans.",
        "source": {
          "id": "kymr_corporate_2026",
          "slide": 51,
          "verified": false
        }
      }
    ]
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "Human genetic validation - IRAK4 null adults are healthy",
        "evidence": "Natural experiment proving safety of complete IRAK4 elimination",
        "confidence": "High - human data"
      },
      {
        "point": "Degrader mechanism uniquely enables full pathway blockade",
        "evidence": "Scaffolding function cannot be blocked by inhibitors",
        "confidence": "High - mechanistic rationale"
      },
      {
        "point": "Sanofi partnership validates target and molecule",
        "evidence": "$150M upfront + $2B milestones; Sanofi prioritized KT-485",
        "confidence": "High - partner conviction"
      },
      {
        "point": "Multiple validated pathways converge on IRAK4",
        "evidence": "IL-1, IL-18, IL-33, IL-36 all signal through IRAK4",
        "confidence": "High - biology well understood"
      },
      {
        "point": "Second-generation addresses QTc issue",
        "evidence": "KT-485 has no QTc signal vs KT-474",
        "confidence": "Medium - need Phase 1 confirmation"
      }
    ],
    "bear_case": [
      {
        "point": "KT-474 QTc issue raises questions about chemistry",
        "evidence": "First-generation had safety signal",
        "counter_argument": "KT-485 specifically designed to eliminate QTc; Sanofi convinced",
        "probability": "Low - if Sanofi is advancing"
      },
      {
        "point": "IRAK4 inhibitors have shown limited efficacy clinically",
        "evidence": "Pfizer and others had disappointing IRAK4i results",
        "counter_argument": "Inhibitors don't block scaffolding function - degraders are different",
        "probability": "Medium - need to prove degrader is better"
      },
      {
        "point": "Sanofi controls development - limited Kymera visibility",
        "evidence": "Sanofi is development lead",
        "counter_argument": "Partnership structure preserves economics; Sanofi has expertise",
        "probability": "Low - partnership risk"
      }
    ],
    "key_debates": [
      {
        "question": "Is scaffolding function blockade clinically meaningful?",
        "bull_view": "Yes - explains why IRAK4 inhibitors failed; degraders will succeed",
        "bear_view": "Unknown - hypothesis not yet proven in humans",
        "what_resolves_it": "KT-485 Phase 2 efficacy vs historical IRAK4 inhibitor data"
      }
    ],
    "economics_to_kymera": {
      "upfront_received": "$150M",
      "potential_milestones": "Up to $2B",
      "royalties": "Tiered double-digit on sales",
      "development_costs": "Borne primarily by Sanofi",
      "net_impact": "Positive NPV with limited ongoing investment"
    }
  },
  "catalysts": [
    {
      "event": "KT-485 Phase 1 initiation",
      "timing": "2026",
      "importance": "Medium",
      "what_to_watch": "Trial start confirmation; initial safety"
    },
    {
      "event": "KT-485 Phase 1 data",
      "timing": "2027 (estimated)",
      "importance": "High",
      "what_to_watch": [
        "IRAK4 degradation",
        "Safety - especially QTc",
        "PK profile",
        "Biomarker changes"
      ]
    }
  ],
  "competitive_landscape": [
    {
      "competitor": "IRAK4 kinase inhibitors",
      "company": "Pfizer, others",
      "companies": "Pfizer (discontinued), others",
      "limitation": "Only block kinase activity, not scaffolding function; disappointing clinical efficacy to date",
      "differentiation": "Inhibitors cannot block scaffolding function; limited efficacy",
      "threat_level": "Low - different mechanism"
    },
    {
      "competitor": "Anti-IL-1 biologics (Anakinra, Canakinumab)",
      "company": "Sobi, Novartis",
      "limitation": "Injectable; only block IL-1 pathway (IRAK4 sits at convergence of IL-1, IL-18, IL-33, IL-36)",
      "differentiation": "Biologics are injectable; IRAK4 degrader is oral and blocks multiple cytokines",
      "threat_level": "Incumbent in some indications"
    },
    {
      "competitor": "Anti-IL-36R (Spesolimab)",
      "company": "Boehringer",
      "limitation": "Injectable; only blocks IL-36 pathway; approved for GPP flares only, not broader I&I",
      "differentiation": "Spesolimab only blocks IL-36; IRAK4 blocks IL-1 + IL-18 + IL-33 + IL-36",
      "threat_level": "Medium - approved for GPP"
    }
  ],
  "ip_landscape": null,
  "sources": [
    {
      "id": "kymr_corporate_2026",
      "type": "corporate_presentation",
      "title": "Kymera Therapeutics Corporate Presentation January 2026",
      "date": "2026-01-15",
      "key_slides": {
        "51": "IRAK4 overview",
        "64": "IRAK4 biology (appendix)"
      }
    }
  ]
}
